Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations failing primary endpoints despite improved safety, underscoring unmet need ...

Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer to ...

Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...

Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...

Patients can now receive treatment in as little as one to two minutes, compared to a 30-minute IV infusion New option offers greater convenience and flexibility in treatment settings, from hospitals ...

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 ...

Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...